Pediatric Blood & Cancer · 2013 · 22 citations · 9 references
MedicinePediatricsPharmacologyChemotherapyPediatric Clinical PharmacologyPediatric OncologyAdverse Effects Of ChemotherapyAntiemetic TherapyNausea AssessmentNausea ControlNausea ManagementPediatric ChemotherapyAcute Chemotherapy-induced NauseaChemotherapy-related ToxicityComplete Response AssessmentHigh-emetogenic Chemotherapy ProphylaxisModerate-emetogenic Chemotherapy ProphylaxisNausea And Vomiting ControlPediatric Antiemetic TherapyPediatric Chemotherapy Safety
Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months-17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%.
9
Development and Validation of a Pictorial Nausea Rating Scale for Children
Amy L. Baxter, Mehernoor F. Watcha, William Baxter et al. · PEDIATRICS · 2011 · 147 citations
Nursing, Child Health, Pediatrics +17
Acute and delayed nausea and emesis control in pediatric oncology patients
Mark T. Holdsworth, Dennis W. Raisch, Jami D. Frost · Cancer · 2006 · 113 citations · Full text
Medicine, Oncology, Pediatrics +15
Lia Gore, Sant P. Chawla, Antônio Sérgio Petrilli et al. · Pediatric Blood & Cancer · 2008 · 99 citations